​

Funding Round

Series B - Tubulis

Series B - Tubulis

Investment Firm

Overview

Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.

Announced Date

Mar 14, 2024

Funding Type

Series B

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

EQT Life Sciences

EQT Life Sciences

EQT Life Sciences is a debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

Nextech Invest

Nextech Invest

Nextech Invest is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

12

Investor Name
Participant InvestorEvotec
Participant InvestorEQT Life Sciences
Participant InvestorBayern Kapital
Participant InvestorAndera Partners
Participant InvestorSeventure Partners

Round Details and Background

Tubulis raised $139300472 on 2024-03-14 in Series B

Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jul 21, 2020
Series A - Tubulis
6-12.3M
May 03, 2022
Series B - Tubulis
9-63.2M
Mar 14, 2024
Series B - Tubulis
13-139.3M
Jul 10, 2017
Grant - Tubulis
-1.5M

Recent Activity

There is no recent news or activity for this profile.